SCHEMBL4664455

SCHEMBL4664455

CC(C)NC(=O)c1cccc(Cl)c1NC(=O)c1cc(C(F)(F)F)nn1-c1ncccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.39
CARM1 Q86X55 3/20 0.38
PDE4B Q07343 3/20 0.38
KLKB1 P03952 3/20 0.38
STIM1 Q13586 1/20 0.38
ORAI1 Q96D31 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
TRPV1 Q8NER1 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29393434 0.94 DHODH (0.39) DHODHCARM1PDE4BKLKB1STIM1
SCHEMBL1380391 0.94 DHODH (0.39) DHODHCARM1PDE4BKLKB1STIM1
SCHEMBL27601648 0.91 PDE4B (0.37) DHODHCARM1PDE4BKLKB1STIM1
SCHEMBL782369 0.91 PDE4B (0.37) DHODHCARM1PDE4BKLKB1STIM1
SCHEMBL12911831 0.90 CARM1 (0.43) DHODHCARM1PDE4BKLKB1STIM1
SCHEMBL13104897 0.89 PDE4B (0.38) DHODHPDE4BMEN1KMT2A
SCHEMBL13104904 0.89 MALT1 (0.38) CARM1PDE4B
SCHEMBL13104851 0.88 KLKB1 (0.38) CARM1PDE4BKLKB1
SCHEMBL951001 0.88 KLKB1 (0.43) CARM1KLKB1STIM1ORAI1MEN1
SCHEMBL14360665 0.88 KDM4E (0.37) DHODHCARM1PDE4BKLKB1STIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1265850-B1 INSECTICIDAL ANTHRANILAMIDES DU PONT (US) 2007-01-03 EP claimed
US-20040142984-A1 Insecticidal anthranilamides FMC CORPORATION 2004-07-22 US claimed
US-6747047-B2 ARTHROPODICIDES E.I. DU PONT DE NEMOURS AND COMPANY 2004-06-08 US claimed
US-20030229050-A1 Insecticidal anthranilamides FMC CORPORATION 2003-12-11 US claimed
EP-1700845-B1 Insecticidal anthranilamides DU PONT (US) 2008-12-10 EP disclosed
US-7338978-B2 Insecticidal anthranilamides E.I. DU PONT DE NEMOURS AND COMPANY (US) 2008-03-04 US disclosed
EP-1265850-B1 INSECTICIDAL ANTHRANILAMIDES DU PONT (US) 2007-01-03 EP disclosed
EP-1700845-A1 Insecticidal anthranilamides E.I.Du pont de nemours and company (US) 2006-09-13 EP disclosed
US-20060079561-A1 Insecticidal anthranilamides FMC CORPORATION 2006-04-13 US disclosed
US-6995178-B2 Insecticidal anthranilamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 2006-02-07 US disclosed
US-20040142984-A1 Insecticidal anthranilamides FMC CORPORATION 2004-07-22 US disclosed
US-6747047-B2 ARTHROPODICIDES E.I. DU PONT DE NEMOURS AND COMPANY 2004-06-08 US disclosed
US-20030229050-A1 Insecticidal anthranilamides FMC CORPORATION 2003-12-11 US disclosed
EP-1265850-A2 INSECTICIDAL ANTHRANILAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 2002-12-18 EP disclosed
WO-2001070671-A2 INSECTICIDAL ANTHRANILAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 2001-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142984-A1 Insecticidal anthranilamides ANTXR2, NIT2, AKR7A2 DHODH 1701/4885CARM1 1742/4885PDE4B 929/4885
US-20060079561-A1 Insecticidal anthranilamides ANTXR2, CYB5R3, NIT2 DHODH 1384/4885CARM1 1777/4885PDE4B 866/4885
US-20030229050-A1 Insecticidal anthranilamides ANTXR2, NIT2, CYB5R3 DHODH 1937/4885CARM1 1812/4885PDE4B 825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.